The global pharmaceutical intermediate market is projected to exceed $35 billion by 2028, driven by the accelerating demand for targeted oncology therapies, antiviral agents, and generics. In this competitive landscape, buyers are increasingly scrutinizing suppliers for batch-to-batch consistency, impurity control, and regulatory compliance—factors that directly impact API quality and time-to-market.

A Rising Specialist in Anticancer Intermediates

Haohong (Qihe) Pharmaceutical Technology Co., Ltd., established in 2021, has rapidly positioned itself as a reliable partner for high-grade pharmaceutical intermediates, particularly for oncology, anti-hepatitis C, and anti-diabetic therapies. Headquartered in the Qihe County High-tech Zone, Shandong Province, the company operates a 3,000㎡ manufacturing facility and a dedicated R&D team of 30 engineers.

Haohong’s production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors, achieving an annual capacity of 1,000 tons. Its export business accounts for 40% of total sales, serving clients across the United States, Europe, Japan, India, Bangladesh, and other regions.

Product Portfolio: Precision Intermediates for Targeted Therapies

Haohong focuses on the development of active pharmaceutical ingredients (APIs) and intermediates for complex molecules. Its core offerings include intermediates for:

• Apalutamide – including 2-Fluoro-4-nitrobenzoic acid (CAS 403-24-7, purity ≥98.0%), N-Methyl-2-fluoro-4-nitrobenzamide (CAS 915087-24-0), and others.
• Abemaciclib – 4-Bromo-2,6-difluoroaniline, 5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine, 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole, among others.
• Alectinib – 2-(4-Ethylphenyl)-2-methylpropanoic acid (CAS 1247119-83-0, purity ≥98%), tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate (CAS 1256584-75-4).

These intermediates serve as key building blocks for anti-cancer drug synthesis, enabling efficient API manufacturing and reducing downstream purification challenges.

Quality Systems and Certifications

Haohong passed ISO 9001:2015 quality management system certification in 2021 and was recognized as a Technology-based Small and Medium-sized Enterprise in 2024. In 2025, it was awarded the title of Innovative Small and Medium-sized Enterprise of Shandong Province. The company also holds multiple utility model patents (e.g., CN202521269185.6, CN202521280279.3) covering specialized production and detection equipment for pharmaceutical intermediates.

Each batch undergoes rigorous QC testing—HPLC, GC, IR, and heavy metal analysis—with purity guarantees of ≥98% to ≥99%. This ensures that Haohong’s intermediates meet the strict requirements of GMP-grade pharmaceutical synthesis.

Real-World Application: Streamlining Cancer Drug R&D

Pharmaceutical intermediates from Haohong are deployed in anti-viral and anti-cancer drug projects across China and international markets. By providing structurally mature, high-purity intermediates, Haohong helps drug developers shorten synthetic routes, reduce production costs, and minimize environmental impact. In one documented case, a top-tier pharmaceutical group achieved:

• ✓ High reaction yield lowering finished drug costs
• ✓ Low impurity and residual solvent levels minimizing safety risks
• ✓ Consistent batch quality improving production repeatability
• ✓ Simplified downstream processes accelerating drug registration

Market Trends and the Demand for Custom Synthesis

The pharmaceutical intermediate market is witnessing a shift toward custom synthesis and flexible supply models. Drug innovators require partners capable of delivering gram-scale samples for R&D to metric-ton commercial batches. Haohong’s tailored services—from structural customization to purity and packaging—align with this trend. The company offers full international trade terms (EXW, FOB, CIF, DDP) and supports 50/50 payment terms with pre-shipment testing.

Future Outlook

With a robust R&D bench, expanding patent portfolio, and growing export footprint, Haohong is well-positioned to serve the increasing demand for high-purity, oncology-focused pharmaceutical intermediates. The company remains committed to the philosophy of "Pragmatism, Innovation, Integrity" and continues to invest in custom synthesis capabilities and GMP-ready production.

Contact – Xu Tianxia | Email: Xutx@haohong-pharma.com | Tel/WhatsApp: +86 180-6854-1569
Address: Block B, Building 3, Accelerator, High-tech Zone, Qihe County, Dezhou City, Shandong, China